Provention Bio Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
174
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.9B
Provention Bio General Information
Description
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.
Contact Information
Website
www.proventionbio.comCorporate Office
- 55 Broad Street
- 2nd Floor
- Red Bank, NJ 07701
- United States
Corporate Office
- 55 Broad Street
- 2nd Floor
- Red Bank, NJ 07701
- United States
Provention Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 27-Apr-2023 | $2.9B | Completed | Generating Revenue | ||
| 4. PIPE | 04-Aug-2022 | Completed | Generating Revenue | |||
| 3. PIPE | 24-Sep-2019 | Completed | Generating Revenue | |||
| 2. IPO | 24-Jul-2018 | $65.4M | $93.8M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 25-Apr-2017 | $28.5M | $28.5M | Completed | Stealth |
Provention Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Provention Bio Comparisons
Industry
Financing
Details
Provention Bio Competitors (79)
One of Provention Bio’s 79 competitors is Xenetic Bioscience, a Corporation company based in Framingham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Xenetic Bioscience | Corporation | Framingham, MA | ||||
| Lisata Therapeutics | Corporate Backed or Acquired | Basking Ridge, NJ | ||||
| Baliopharm | Corporate Backed or Acquired | Basel, Switzerland | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY |
Provention Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Provention Bio Patents
Provention Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230382993-A1 | Methods and compositions for preventing or delaying type 1 diabetes | Pending | 24-May-2022 | ||
| AU-2023275531-A1 | Methods and compositions for preventing or delaying type 1 diabetes | Pending | 24-May-2022 | ||
| EP-4532552-A1 | Methods and compositions for preventing or delaying type 1 diabetes | Pending | 24-May-2022 | ||
| CA-3242085-A1 | Methods and compositions for treating barth syndrome | Pending | 23-Dec-2021 | ||
| EP-4453040-A2 | Methods and compositions for treating barth syndrome | Pending | 23-Dec-2021 | C07K16/283 |
Provention Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Provention Bio Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amgen | Corporation | Minority | ||
| Armistice Capital | Hedge Fund | Minority | ||
| Johnson & Johnson Innovation - JJDC | Corporate Venture Capital | Minority | ||
| MDB Capital Holdings | Investment Bank | Minority | ||
| Macrogenics | Corporation | Minority |
Provention Bio Investments (1)
Provention Bio’s most recent deal was a Corporate Asset Purchase with MacroGenics (Anti-CD3 Monoclonal Antibody Teplizumab). The deal was made on 09-May-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MacroGenics (Anti-CD3 Monoclonal Antibody Teplizumab) | 09-May-2018 | Corporate Asset Purchase | Buildings and Property |
Provention Bio ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
39.58 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Pharmaceuticals
Industry
of 898
Rank
Percentile
Pharmaceuticals
Subindustry
of 428
Rank
Percentile
Provention Bio FAQs
-
When was Provention Bio founded?
Provention Bio was founded in 2016.
-
Where is Provention Bio headquartered?
Provention Bio is headquartered in Red Bank, NJ.
-
What is the size of Provention Bio?
Provention Bio has 174 total employees.
-
What industry is Provention Bio in?
Provention Bio’s primary industry is Biotechnology.
-
Is Provention Bio a private or public company?
Provention Bio is a Private company.
-
What is the current valuation of Provention Bio?
The current valuation of Provention Bio is .
-
What is Provention Bio’s current revenue?
The current revenue for Provention Bio is .
-
How much funding has Provention Bio raised over time?
Provention Bio has raised $174M.
-
Who are Provention Bio’s investors?
Amgen, Armistice Capital, Johnson & Johnson Innovation - JJDC, MDB Capital Holdings, and Macrogenics are 5 of 9 investors who have invested in Provention Bio.
-
Who are Provention Bio’s competitors?
Xenetic Bioscience, Lisata Therapeutics, Baliopharm, Incyte, and Regeneron Pharmaceuticals are some of the 79 competitors of Provention Bio.
-
When was Provention Bio acquired?
Provention Bio was acquired on 27-Apr-2023.
-
Who acquired Provention Bio?
Provention Bio was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
